Autoinflammatory diseases are caused by inappropriate or excessive activation of innate immune pathways. When unchecked, this excessive inflammation can result in tissue damage, organ failure, and death. The Translational Genetics and Genomics Section (TGGS) aims to identify mechanisms of autoinflammatory pathophysiology and translate these insights into new or improved therapeutic approaches to treat inflammatory diseases.
Systemic autoinflammatory diseases are rare, familial inflammatory conditions caused by mutations in individual genes. Other autoinflammatory conditions do not demonstrate familial inheritance, instead showing a more complicated, polygenic inheritance. Still's disease, which includes systemic juvenile idiopathic arthritis (sJIA) in children and adult-onset Still's disease (AOSD) in adults, is one such condition.
Still's disease is a severe, systemic inflammatory condition that is characterized by periods of prolonged, unexplained fever and chronic arthritis, together with inflammation of the skin and organs. The complications of Still's disease can be life-threatening. They include macrophage activation syndrome (MAS), a cytokine storm syndrome, and an emergent form of interstitial lung disease strongly associated with the DR15 ancestral HLA haplotype, which develops in the context of an atypical hypersensitivity reaction to a group of cytokine inhibitors.
The TGGS was established in 2013 to identify genetic factors that contribute to the development of Still's disease and other genetically complex autoinflammatory diseases. In its earliest days, members of the TGGS performed the first genomic studies of Still's disease, which yielded various new and unexpected insights. In 2018, the TGGS established a natural history protocol at the NIH Clinical Center, which provided an infrastructure for integrated genomic and immunologic investigations of children and adults with Still's disease and other genetically complex forms of autoinflammation.
Current projects include:
- Family-based genomics of Still's disease.
- Molecular classification of children and adults with refractory forms of Still's disease.
- Genomics of Still's disease-associated lung disease.
- Pharmacogenomics of Still's disease.
- Detailed clinical and functional characterization of PLCG2-associated immune dysregulation.
Michael Ombrello, M.D., is an adult and pediatric rheumatologist. He completed his undergraduate degree (1997) and medical degree (2002) at Saint Louis University. Upon completing a Combined Adult and Pediatric Rheumatology Fellowship, he was awarded the 2010 Distinguished Fellow Award from the American College of Rheumatology. Dr. Ombrello was an inaugural NIAMS Henry Metzger Scholar in Translational Research. He completed an additional two-year postdoctoral fellowship in the Inflammatory Disease Section of the National Human Genome Research Institute.
Dr. Ombrello is currently a Tenure-Track Investigator at the NIAMS. His research program focuses on discovering genetic causes of rare inflammatory diseases in humans, translating those discoveries into an improved understanding of inflammatory pathophysiology, and identifying new therapeutic targets for treating inflammatory diseases.
Over the past decade, Dr. Ombrello has been a pioneer in Still's disease genomics, leading the investigations of the International Childhood Genetics (INCHARGE) Consortium. His studies unexpectedly implicated adaptive immune mechanisms and unambiguously demonstrated that the unique genetic architecture of Still's disease distinguishes it from the other forms of childhood arthritis. His group has also identified the first genetic biomarkers that may guide the future treatment of Still's disease. These include one that identifies non-responders to a commonly used treatment and another that strongly predicts which subjects will develop a potentially fatal hypersensitivity reaction to a group of widely used therapies.
In addition to studying Still's disease, Dr. Ombrello described the first disease-causing mutations of PLCG2 in humans. His group continues to engage in clinical and translational investigations of immune-mediated disease caused by PLCG2 variation.
Dr. Ombrello has received numerous NIH honors and awards, most notably the NIH Fellows Award for Research Excellence, Merit Awards from NIAMS and NIAID, and the NIH Director's Award.
Dr. Ombrello is firmly committed to mentoring and training the next generation of investigators within and beyond the NIH community. He served a 4-year term on the American College of Rheumatology's Early Career Investigator subcommittee, during which he worked to develop and deliver career development content to early career rheumatologist-scientists. However, his commitment to mentorship is best reflected by the success of his NIAMS lab members, whose research accomplishments have also been recognized with many local and national awards. These include the Distinguished Fellow Award from the American College of Rheumatology, multiple recipients of the NIH Fellows Award for Research Excellence, and numerous "Best Presentation awards from national and international scientific meetings.
- Saper VE, Ombrello MJ, Tremoulet AH, Montero-Martin G, Prahalad S, Canna S, Shimizu C, Deutsch G, Tan SY, Remmers EF, Monos D, Hahn T, Phadke OK, Cassidy E, Ferguson I, Mallajosyula V, Xu J, Rosa Duque JS, Chua GT, Ghosh D, Szymanski AM, Rubin D, Burns JC, Tian L, Fernandez-Vina MA, Mellins ED, Hollenbach JA, Drug Hypersensitivity Consortium., INCHARGE Consortium.. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis. 2022;81(3):406-415.
- Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM, INCHARGE Consortium., Thomson W, Kastner DL, Woo P, Ombrello MJ. IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2018;70(8):1319-1330.
- Ombrello MJ, Arthur VL, Remmers EF, Hinks A, Tachmazidou I, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rosen-Wolff A, Minden K, Tenbrock K, Demirkaya E, Cobb J, Baskin E, Signa S, Shuldiner E, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcón-Riquelme ME, Docampo E, Estivill X, Gül A, British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group, Inception Cohort of Newly Diagnosed Patients with Juvenile Idiopathic Arthritis (ICON-JIA) Study Group, Childhood Arthritis Prospective Study (CAPS) Group, Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators, Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group, Biologically Based Outcome Predictors in JIA (BBOP) Group., Langefeld CD, Thompson S, Zeggini E, Kastner DL, Woo P, Thomson W. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis. 2017;76(5):906-913.
- Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Mellins ED, Ilowite NT, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg A, Wedderburn LR, Anton J, Schwarz T, Hinks A, Bilginer Y, Park J, Cobb J, Satorius CL, Han B, Baskin E, Signa S, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcón-Riquelme ME, Docampo E, Estivill X, Gül A, British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group., Childhood Arthritis Prospective Study (CAPS) Group., Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators., Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group., Biologically Based Outcome Predictors in JIA (BBOP) Group., de Bakker PI, Raychaudhuri S, Langefeld CD, Thompson S, Zeggini E, Thomson W, Kastner DL, Woo P, International Childhood Arthritis Genetics (INCHARGE) Consortium.. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A. 2015;112(52):15970-5.
- Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, Subramanian N, Bunney TD, Baxendale RW, Martins MS, Romberg N, Komarow H, Aksentijevich I, Kim HS, Ho J, Cruse G, Jung MY, Gilfillan AM, Metcalfe DD, Nelson C, O'Brien M, Wisch L, Stone K, Douek DC, Gandhi C, Wanderer AA, Lee H, Nelson SF, Shianna KV, Cirulli ET, Goldstein DB, Long EO, Moir S, Meffre E, Holland SM, Kastner DL, Katan M, Hoffman HM, Milner JD. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med. 2012;366(4):330-8.
Related Scientific Focus Areas
Genetics and Genomics
View additional Principal Investigators in Genetics and Genomics
View additional Principal Investigators in Computational Biology
Molecular Biology and Biochemistry
View additional Principal Investigators in Molecular Biology and Biochemistry
This page was last updated on Thursday, November 10, 2022